Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Dr. Pengchong Wang | Cancer Therapy | Best Researcher Award

Shaanxi Provincial People’s Hospital | China

AUTHOR PROFILE

Scopus

πŸ’Š WANG PENGCHONG: ACADEMIC PROFILE AND ACHIEVEMENTS πŸŽ“


πŸŽ“EARLY ACADEMIC PURSUITS πŸ“š

Wang Pengchong, the Chief Pharmacist at Shaanxi Provincial People’s Hospital, earned his PhD in Pharmacy from Xi’an Jiaotong University. His academic journey was shaped by a focus on tumor pharmacy and targeted drug delivery systems. His early years were spent delving into the intricacies of pharmaceutical care, particularly in the context of oncology, laying the foundation for his future breakthroughs.

πŸ’Ό PROFESSIONAL ENDEAVORS πŸ₯

Wang is a dedicated member of the Pharmaceutical Care Committee of the Shaanxi Pharmacological Society. His professional work has revolved around tumor pharmacology, pioneering approaches to targeted cancer treatments. He has played an instrumental role in several major projects, including three general projects funded by the National Natural Science Foundation of China and two key R&D projects in Shaanxi Province. His leadership in high-profile initiatives highlights his influence on pharmaceutical advancements.

πŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS 🎯

Wang Pengchong’s research is centered on targeted drug delivery systems and tumor pharmacy research. His contributions are geared toward improving cancer therapies by focusing on precision medicine, which minimizes side effects and enhances the effectiveness of treatment. His work extends into innovative methods, such as nanotechnology in drug targeting. Wang has led multiple significant projects, including the Shaanxi Province Science and Technology Plan Project, the Xi’an City Science and Technology Plan Project, and the Yaodong Shenzhou Pharmaceutical Research Capacity Building Project.

✨ IMPACT AND INFLUENCE 🌐

Wang’s research has had a profound impact on cancer treatment strategies and pharmaceutical care. His efforts have advanced both the scientific understanding and practical application of cancer drugs, particularly in how they can be precisely targeted to tumor cells while sparing healthy tissues. Through his leadership in government-backed research initiatives, Wang has become a driving force in the field, influencing not just Shaanxi Province but the broader pharmaceutical landscape.

πŸ“Š ACADEMIC CITES πŸ“„

In the past five years, Wang Pengchong has published more than ten SCI-indexed papers in international journals. His work is widely cited, particularly in oncology and pharmaceutical sciences. His research topics span from cutting-edge drug delivery systems to therapeutic advancements, solidifying his reputation in the global scientific community.

🌍 LEGACY AND FUTURE CONTRIBUTIONS πŸ†

Wang Pengchong’s legacy will continue to grow as he contributes to targeted cancer therapies and pharmaceutical innovations. His role in advancing precision medicine ensures that his work will influence the next generation of cancer treatments. By leading critical projects and setting new benchmarks in oncology pharmacy, Wang is shaping the future of drug delivery systems and cancer care. His ongoing commitment to pharmaceutical research guarantees that his contributions will leave a lasting impact on the field.

πŸ“ˆ CONCLUSION 🌟

Wang Pengchong’s distinguished career as a Chief Pharmacist and researcher has made significant strides in the fields of targeted drug delivery systems and tumor pharmacy. His academic foundation, coupled with leadership in high-impact research projects, has not only advanced cancer treatment but also positioned him as a key contributor to pharmaceutical sciences. With over a decade of impactful publications and successful project leadership, Wang’s research continues to shape the future of oncology treatments, fostering innovations that will benefit patients worldwide. His work embodies a lasting legacy of precision medicine and cutting-edge cancer therapies, ensuring he remains a pivotal figure in pharmaceutical research and development. πŸŒπŸ”¬

 

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

 

    • Mucoadhesive nanoparticles-based oral drug delivery systems enhance ameliorative effects of low molecular weight heparin on experimental colitis
      • Authors: Yan, Y., Sun, Y., Wang, P., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2020

     

    • An improved synthesis of water-soluble dual fluorescence emission carbon dots from holly leaves for accurate detection of mercury ions in living cells
      • Authors: Wang, P., Yan, Y., Zhang, Y., Xing, J., Dong, Y.
      • Journal: International Journal of Nanomedicine
      • Year: 2021

     

    • One-pot synthesis of nuclear targeting carbon dots with high photoluminescence
      • Authors: Wang, P., Ji, H., Guo, S., Xing, J., Dong, Y.
      • Journal: Chinese Chemical Letters
      • Year: 2021

     

    • Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis
      • Authors: Wang, P., Zhang, Y., Lei, H., Xing, J., Dong, Y.
      • Journal: Carbohydrate Polymers
      • Year: 2023

     

    • Multifunctional nanosystems sequentially regulating intratumor Fenton chemistry by remodeling the tumor microenvironment to reinforce chemodynamic therapy
      • Authors: Dong, K., Chen, W., Zhao, Z., Lu, T., Dong, Y.
      • Journal: Biomaterials Advances
      • Year: 2022

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Dr. Stavros Melemenidis | Micrometastases | Best Researcher Award

Stanford University School of Medicine | United States

Author Profile

Scopus

Orcid id

πŸ“š Biography: Dr. Stavros Melemenidis

πŸŽ“ Education

  • DPhil in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2010-2015)
    • Mentors: Prof. Nicola Sibson, Prof. Ruth Muschel
    • Thesis: Development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis
  • M.Sc. in Radiation Biology – University of Oxford, Dept. Radiation Oncology, Oxford, UK (2009-2010)
  • M.Sc. in Radiometrics – University of Liverpool, Dept. Physics, Liverpool, UK (2008-2009)
  • B.Sc. in Physics: Medical Applications – University of Liverpool, Dept. Physics, Liverpool, UK (2005-2008)
  • A.Eng. in PC Systems and Peripheral Equipment – IIEK Neapoleos, Technical College, Thessaloniki, Greece (1998-2000)
  • Cert. Medical Physics – UCLA, Dept. Radiation Oncology, Los Angeles, CA, USA (2022-2023)

🏒 Current Position

  • Director of Pre-clinical Radiotherapy – Dept. of Radiation Oncology, Stanford University (Jan 2023-present)
  • Research Scientist – Div. of Radiation Therapy, Stanford University (Feb 2020-present)

πŸ”¬ Research Experience & Skills

  • Stanford University, Dept. Radiation Oncology, Stanford, CA
    • Director of Pre-clinical Radiotherapy Core (Jun 2023-present)
      • Calibration of preclinical orthovoltage irradiators
      • Monthly and annual quality checks for dosimetric consistency
      • Innovation in animal radiation shielding via 3D design and additive manufacturing
    • Basic Life Research Scientist at Div. of Radiation Therapy (Jun 2020-present)
      • Pioneering preclinical ultra-high dose-rate (FLASH) irradiation experiments
      • Specializing in 3D-designed radiation shielding for animal safety
      • Expertise in dosimetry using radiochromic film and ion chambers
      • Development of animal models involving tumor implantation and microsurgical techniques
    • Postdoctoral Fellow (Feb 2016-Jun 2020)
      • Advisor: Edward E. Graves
      • Led development of in vivo mouse tumor models integrating imaging, radiotherapy, and immunotherapy
      • Specialized in ultrasound-guided injection techniques
      • Conducted research into immune cell migration with a focus on macrophage imaging
      • Evaluated radioprotective strategies for healthy tissue through drug development
    • Postdoctoral Fellow at University of Oxford, Dept. Radiation Oncology (Jan 2015-Sep 2015)
      • Advisor: Nicola R. Sibson
      • Designed and evaluated innovative imaging probes for metastasis detection and angiogenesis visualization
      • Developed dual MRI/PET probe for metastasis and MRI probe for angiogenesis
      • Managed international research collaboration with Duke University

πŸ“œ Selected Publications

  • In vivo PET detection of lung micrometastasis by targeting endothelial VCAM-1. Int J Mol Sci, 2024.
  • Multi-institutional audit of FLASH and conventional dosimetry with a 3D-printed anatomically realistic mouse phantom. Int J Radiat Oncol Biol Phys, 2023.
  • Exploring deep learning for estimating the isoeffective dose of FLASH irradiation from mouse intestinal histological images. J Radiat Oncol Biol Phys, 2023.
  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation. Integr Biol (Camb), 2023.
  • Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. J Clin Invest, 2023.

πŸ† Awards & Honors

  • Recognition of Excellent Research: Aegean Conferences: 12th International Conference on Complement Therapeutics, Rhodes, Greece, 2019
  • Poster Prize: Aegean Conferences: 3rd International Conference for Tumor Microenvironment and Cellular Stress, Greece, Mykonos, 2014

πŸ—£οΈ Conference Presentations

  • Oral Presentation: Demonstrating FLASH effectiveness against CONV dose rates, 34th ACRO Summit, Orlando, FL, March 2024
  • Poster Presentation: Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation, 65th ASTRO Annual Meeting San Diego, USA, Oct 2023

πŸ“ž References

  • Prof. Billy W Loo Jr: Professor of Radiation Oncology (Radiation Therapy), Stanford University School of Medicine
  • Prof. Edward E Graves: Associate Professor of Radiation Oncology and Director of Molecular Imaging Program, Stanford University School of Medicine
  • Prof. Frederick M Dirbas: Associate Professor of Surgery (General Surgery), Stanford University School of Medicine

Dr. Stavros Melemenidis is a distinguished figure in radiation oncology, with a profound impact on preclinical radiotherapy and FLASH irradiation research. His contributions to innovative imaging techniques and his dedication to advancing cancer treatment methodologies are reflected in his extensive publication record and numerous accolades.

πŸ“ŠπŸ”¬Notable Publication: